Copyright Reports & Markets. All rights reserved.

Global CD161 Antibody Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of CD161 Antibody
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of CD161 Antibody by Type
    • 1.3.1 Overview: Global CD161 Antibody Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global CD161 Antibody Consumption Value Market Share by Type in 2022
    • 1.3.3 Monoclonal
    • 1.3.4 Polyclonal
  • 1.4 Global CD161 Antibody Market by Application
    • 1.4.1 Overview: Global CD161 Antibody Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Immunochemistry (IHC)
    • 1.4.3 Immunofluorescence (IF)
    • 1.4.4 Immunoprecipitation (IP)
    • 1.4.5 Western Blot (WB)
    • 1.4.6 ELISA
    • 1.4.7 Others
  • 1.5 Global CD161 Antibody Market Size & Forecast
  • 1.6 Global CD161 Antibody Market Size and Forecast by Region
    • 1.6.1 Global CD161 Antibody Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global CD161 Antibody Market Size by Region, (2018-2029)
    • 1.6.3 North America CD161 Antibody Market Size and Prospect (2018-2029)
    • 1.6.4 Europe CD161 Antibody Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific CD161 Antibody Market Size and Prospect (2018-2029)
    • 1.6.6 South America CD161 Antibody Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa CD161 Antibody Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 BD Biosciences
    • 2.1.1 BD Biosciences Details
    • 2.1.2 BD Biosciences Major Business
    • 2.1.3 BD Biosciences CD161 Antibody Product and Solutions
    • 2.1.4 BD Biosciences CD161 Antibody Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 BD Biosciences Recent Developments and Future Plans
  • 2.2 GeneTex
    • 2.2.1 GeneTex Details
    • 2.2.2 GeneTex Major Business
    • 2.2.3 GeneTex CD161 Antibody Product and Solutions
    • 2.2.4 GeneTex CD161 Antibody Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 GeneTex Recent Developments and Future Plans
  • 2.3 RayBiotech
    • 2.3.1 RayBiotech Details
    • 2.3.2 RayBiotech Major Business
    • 2.3.3 RayBiotech CD161 Antibody Product and Solutions
    • 2.3.4 RayBiotech CD161 Antibody Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 RayBiotech Recent Developments and Future Plans
  • 2.4 LifeSpan BioSciences
    • 2.4.1 LifeSpan BioSciences Details
    • 2.4.2 LifeSpan BioSciences Major Business
    • 2.4.3 LifeSpan BioSciences CD161 Antibody Product and Solutions
    • 2.4.4 LifeSpan BioSciences CD161 Antibody Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 LifeSpan BioSciences Recent Developments and Future Plans
  • 2.5 BioLegend
    • 2.5.1 BioLegend Details
    • 2.5.2 BioLegend Major Business
    • 2.5.3 BioLegend CD161 Antibody Product and Solutions
    • 2.5.4 BioLegend CD161 Antibody Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 BioLegend Recent Developments and Future Plans
  • 2.6 Abeomics
    • 2.6.1 Abeomics Details
    • 2.6.2 Abeomics Major Business
    • 2.6.3 Abeomics CD161 Antibody Product and Solutions
    • 2.6.4 Abeomics CD161 Antibody Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Abeomics Recent Developments and Future Plans
  • 2.7 Bioss
    • 2.7.1 Bioss Details
    • 2.7.2 Bioss Major Business
    • 2.7.3 Bioss CD161 Antibody Product and Solutions
    • 2.7.4 Bioss CD161 Antibody Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Bioss Recent Developments and Future Plans
  • 2.8 Novus Biologicals
    • 2.8.1 Novus Biologicals Details
    • 2.8.2 Novus Biologicals Major Business
    • 2.8.3 Novus Biologicals CD161 Antibody Product and Solutions
    • 2.8.4 Novus Biologicals CD161 Antibody Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Novus Biologicals Recent Developments and Future Plans
  • 2.9 Tonbo Biosciences
    • 2.9.1 Tonbo Biosciences Details
    • 2.9.2 Tonbo Biosciences Major Business
    • 2.9.3 Tonbo Biosciences CD161 Antibody Product and Solutions
    • 2.9.4 Tonbo Biosciences CD161 Antibody Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Tonbo Biosciences Recent Developments and Future Plans
  • 2.10 Bio-Rad
    • 2.10.1 Bio-Rad Details
    • 2.10.2 Bio-Rad Major Business
    • 2.10.3 Bio-Rad CD161 Antibody Product and Solutions
    • 2.10.4 Bio-Rad CD161 Antibody Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Bio-Rad Recent Developments and Future Plans
  • 2.11 Cell Sciences
    • 2.11.1 Cell Sciences Details
    • 2.11.2 Cell Sciences Major Business
    • 2.11.3 Cell Sciences CD161 Antibody Product and Solutions
    • 2.11.4 Cell Sciences CD161 Antibody Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 Cell Sciences Recent Developments and Future Plans
  • 2.12 Miltenyi Biotec
    • 2.12.1 Miltenyi Biotec Details
    • 2.12.2 Miltenyi Biotec Major Business
    • 2.12.3 Miltenyi Biotec CD161 Antibody Product and Solutions
    • 2.12.4 Miltenyi Biotec CD161 Antibody Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 Miltenyi Biotec Recent Developments and Future Plans
  • 2.13 R&D Systems
    • 2.13.1 R&D Systems Details
    • 2.13.2 R&D Systems Major Business
    • 2.13.3 R&D Systems CD161 Antibody Product and Solutions
    • 2.13.4 R&D Systems CD161 Antibody Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 R&D Systems Recent Developments and Future Plans
  • 2.14 BMA Biomedicals
    • 2.14.1 BMA Biomedicals Details
    • 2.14.2 BMA Biomedicals Major Business
    • 2.14.3 BMA Biomedicals CD161 Antibody Product and Solutions
    • 2.14.4 BMA Biomedicals CD161 Antibody Revenue, Gross Margin and Market Share (2018-2023)
    • 2.14.5 BMA Biomedicals Recent Developments and Future Plans
  • 2.15 AAT Bioquest
    • 2.15.1 AAT Bioquest Details
    • 2.15.2 AAT Bioquest Major Business
    • 2.15.3 AAT Bioquest CD161 Antibody Product and Solutions
    • 2.15.4 AAT Bioquest CD161 Antibody Revenue, Gross Margin and Market Share (2018-2023)
    • 2.15.5 AAT Bioquest Recent Developments and Future Plans
  • 2.16 Biobyt
    • 2.16.1 Biobyt Details
    • 2.16.2 Biobyt Major Business
    • 2.16.3 Biobyt CD161 Antibody Product and Solutions
    • 2.16.4 Biobyt CD161 Antibody Revenue, Gross Margin and Market Share (2018-2023)
    • 2.16.5 Biobyt Recent Developments and Future Plans
  • 2.17 Jingjie PTM BioLab
    • 2.17.1 Jingjie PTM BioLab Details
    • 2.17.2 Jingjie PTM BioLab Major Business
    • 2.17.3 Jingjie PTM BioLab CD161 Antibody Product and Solutions
    • 2.17.4 Jingjie PTM BioLab CD161 Antibody Revenue, Gross Margin and Market Share (2018-2023)
    • 2.17.5 Jingjie PTM BioLab Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global CD161 Antibody Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of CD161 Antibody by Company Revenue
    • 3.2.2 Top 3 CD161 Antibody Players Market Share in 2022
    • 3.2.3 Top 6 CD161 Antibody Players Market Share in 2022
  • 3.3 CD161 Antibody Market: Overall Company Footprint Analysis
    • 3.3.1 CD161 Antibody Market: Region Footprint
    • 3.3.2 CD161 Antibody Market: Company Product Type Footprint
    • 3.3.3 CD161 Antibody Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global CD161 Antibody Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global CD161 Antibody Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global CD161 Antibody Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global CD161 Antibody Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America CD161 Antibody Consumption Value by Type (2018-2029)
  • 6.2 North America CD161 Antibody Consumption Value by Application (2018-2029)
  • 6.3 North America CD161 Antibody Market Size by Country
    • 6.3.1 North America CD161 Antibody Consumption Value by Country (2018-2029)
    • 6.3.2 United States CD161 Antibody Market Size and Forecast (2018-2029)
    • 6.3.3 Canada CD161 Antibody Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico CD161 Antibody Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe CD161 Antibody Consumption Value by Type (2018-2029)
  • 7.2 Europe CD161 Antibody Consumption Value by Application (2018-2029)
  • 7.3 Europe CD161 Antibody Market Size by Country
    • 7.3.1 Europe CD161 Antibody Consumption Value by Country (2018-2029)
    • 7.3.2 Germany CD161 Antibody Market Size and Forecast (2018-2029)
    • 7.3.3 France CD161 Antibody Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom CD161 Antibody Market Size and Forecast (2018-2029)
    • 7.3.5 Russia CD161 Antibody Market Size and Forecast (2018-2029)
    • 7.3.6 Italy CD161 Antibody Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific CD161 Antibody Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific CD161 Antibody Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific CD161 Antibody Market Size by Region
    • 8.3.1 Asia-Pacific CD161 Antibody Consumption Value by Region (2018-2029)
    • 8.3.2 China CD161 Antibody Market Size and Forecast (2018-2029)
    • 8.3.3 Japan CD161 Antibody Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea CD161 Antibody Market Size and Forecast (2018-2029)
    • 8.3.5 India CD161 Antibody Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia CD161 Antibody Market Size and Forecast (2018-2029)
    • 8.3.7 Australia CD161 Antibody Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America CD161 Antibody Consumption Value by Type (2018-2029)
  • 9.2 South America CD161 Antibody Consumption Value by Application (2018-2029)
  • 9.3 South America CD161 Antibody Market Size by Country
    • 9.3.1 South America CD161 Antibody Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil CD161 Antibody Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina CD161 Antibody Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa CD161 Antibody Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa CD161 Antibody Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa CD161 Antibody Market Size by Country
    • 10.3.1 Middle East & Africa CD161 Antibody Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey CD161 Antibody Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia CD161 Antibody Market Size and Forecast (2018-2029)
    • 10.3.4 UAE CD161 Antibody Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 CD161 Antibody Market Drivers
  • 11.2 CD161 Antibody Market Restraints
  • 11.3 CD161 Antibody Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry
  • 11.5 Influence of COVID-19 and Russia-Ukraine War
    • 11.5.1 Influence of COVID-19
    • 11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

  • 12.1 CD161 Antibody Industry Chain
  • 12.2 CD161 Antibody Upstream Analysis
  • 12.3 CD161 Antibody Midstream Analysis
  • 12.4 CD161 Antibody Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global CD161 Antibody market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
    This report is a detailed and comprehensive analysis for global CD161 Antibody market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
    Key Features:
    Global CD161 Antibody market size and forecasts, in consumption value ($ Million), 2018-2029
    Global CD161 Antibody market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
    Global CD161 Antibody market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
    Global CD161 Antibody market shares of main players, in revenue ($ Million), 2018-2023.
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for CD161 Antibody
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace.
    This report profiles key players in the global CD161 Antibody market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include BD Biosciences, GeneTex, RayBiotech, LifeSpan BioSciences and BioLegend, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
    Market segmentation
    CD161 Antibody market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Monoclonal
    Polyclonal
    Market segment by Application
    Immunochemistry (IHC)
    Immunofluorescence (IF)
    Immunoprecipitation (IP)
    Western Blot (WB)
    ELISA
    Others
    Market segment by players, this report covers
    BD Biosciences
    GeneTex
    RayBiotech
    LifeSpan BioSciences
    BioLegend
    Abeomics
    Bioss
    Novus Biologicals
    Tonbo Biosciences
    Bio-Rad
    Cell Sciences
    Miltenyi Biotec
    R&D Systems
    BMA Biomedicals
    AAT Bioquest
    Biobyt
    Jingjie PTM BioLab
    Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe CD161 Antibody product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of CD161 Antibody, with revenue, gross margin and global market share of CD161 Antibody from 2018 to 2023.
    Chapter 3, the CD161 Antibody competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and CD161 Antibody market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
    Chapter 12, the key raw materials and key suppliers, and industry chain of CD161 Antibody.
    Chapter 13, to describe CD161 Antibody research findings and conclusion.

    Buy now